vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $236.8M, roughly 1.4× CROSS COUNTRY HEALTHCARE INC). HAEMONETICS CORP runs the higher net margin — 13.2% vs -35.0%, a 48.2% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -23.6%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $16.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CCRN vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $339.0M |
| Net Profit | $-82.9M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | -30.2% | 19.9% |
| Net Margin | -35.0% | 13.2% |
| Revenue YoY | -23.6% | -2.7% |
| Net Profit YoY | -2109.7% | 19.3% |
| EPS (diluted) | $-2.56 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $339.0M | ||
| Q3 25 | $250.1M | $327.3M | ||
| Q2 25 | $274.1M | $321.4M | ||
| Q1 25 | $293.4M | $330.6M | ||
| Q4 24 | $309.9M | $348.5M | ||
| Q3 24 | $315.1M | $345.5M | ||
| Q2 24 | $339.8M | $336.2M | ||
| Q1 24 | $379.2M | — |
| Q4 25 | $-82.9M | $44.7M | ||
| Q3 25 | $-4.8M | $38.7M | ||
| Q2 25 | $-6.7M | $34.0M | ||
| Q1 25 | $-490.0K | $58.0M | ||
| Q4 24 | $-3.8M | $37.5M | ||
| Q3 24 | $2.6M | $33.8M | ||
| Q2 24 | $-16.1M | $38.4M | ||
| Q1 24 | $2.7M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | 20.4% | 59.5% | ||
| Q2 25 | 20.4% | 59.8% | ||
| Q1 25 | 20.0% | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | 20.4% | 54.2% | ||
| Q2 24 | 20.8% | 52.0% | ||
| Q1 24 | 20.4% | — |
| Q4 25 | -30.2% | 19.9% | ||
| Q3 25 | -2.4% | 17.9% | ||
| Q2 25 | -2.1% | 16.8% | ||
| Q1 25 | -0.3% | 21.6% | ||
| Q4 24 | -1.1% | 16.9% | ||
| Q3 24 | 0.9% | 15.0% | ||
| Q2 24 | -5.7% | 11.8% | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -35.0% | 13.2% | ||
| Q3 25 | -1.9% | 11.8% | ||
| Q2 25 | -2.4% | 10.6% | ||
| Q1 25 | -0.2% | 17.5% | ||
| Q4 24 | -1.2% | 10.8% | ||
| Q3 24 | 0.8% | 9.8% | ||
| Q2 24 | -4.7% | 11.4% | ||
| Q1 24 | 0.7% | — |
| Q4 25 | $-2.56 | $0.95 | ||
| Q3 25 | $-0.15 | $0.81 | ||
| Q2 25 | $-0.20 | $0.70 | ||
| Q1 25 | $-0.02 | $1.17 | ||
| Q4 24 | $-0.13 | $0.74 | ||
| Q3 24 | $0.08 | $0.66 | ||
| Q2 24 | $-0.47 | $0.74 | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $322.8M | $911.5M |
| Total Assets | $449.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $363.4M | ||
| Q3 25 | $99.1M | $296.4M | ||
| Q2 25 | $81.2M | $292.9M | ||
| Q1 25 | $80.7M | $306.8M | ||
| Q4 24 | $81.6M | $320.8M | ||
| Q3 24 | $64.0M | $299.3M | ||
| Q2 24 | $69.6M | $344.4M | ||
| Q1 24 | $5.2M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $322.8M | $911.5M | ||
| Q3 25 | $408.1M | $849.2M | ||
| Q2 25 | $412.2M | $882.3M | ||
| Q1 25 | $418.2M | $820.8M | ||
| Q4 24 | $419.0M | $906.9M | ||
| Q3 24 | $424.7M | $878.9M | ||
| Q2 24 | $433.3M | $905.4M | ||
| Q1 24 | $462.4M | — |
| Q4 25 | $449.0M | $2.5B | ||
| Q3 25 | $538.2M | $2.4B | ||
| Q2 25 | $553.8M | $2.5B | ||
| Q1 25 | $576.2M | $2.5B | ||
| Q4 24 | $589.3M | $2.5B | ||
| Q3 24 | $597.4M | $2.5B | ||
| Q2 24 | $602.9M | $2.5B | ||
| Q1 24 | $648.4M | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $93.6M |
| Free Cash FlowOCF − Capex | $16.1M | $87.2M |
| FCF MarginFCF / Revenue | 6.8% | 25.7% |
| Capex IntensityCapex / Revenue | 0.9% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $93.6M | ||
| Q3 25 | $20.1M | $111.3M | ||
| Q2 25 | $4.2M | $17.4M | ||
| Q1 25 | $5.7M | $116.6M | ||
| Q4 24 | $24.2M | $43.8M | ||
| Q3 24 | $7.5M | $48.8M | ||
| Q2 24 | $82.4M | $-27.4M | ||
| Q1 24 | $6.0M | — |
| Q4 25 | $16.1M | $87.2M | ||
| Q3 25 | $17.9M | $106.3M | ||
| Q2 25 | $2.3M | $13.6M | ||
| Q1 25 | $3.8M | $100.9M | ||
| Q4 24 | $21.7M | $35.2M | ||
| Q3 24 | $6.3M | $39.4M | ||
| Q2 24 | $79.6M | $-33.1M | ||
| Q1 24 | $3.8M | — |
| Q4 25 | 6.8% | 25.7% | ||
| Q3 25 | 7.2% | 32.5% | ||
| Q2 25 | 0.8% | 4.2% | ||
| Q1 25 | 1.3% | 30.5% | ||
| Q4 24 | 7.0% | 10.1% | ||
| Q3 24 | 2.0% | 11.4% | ||
| Q2 24 | 23.4% | -9.8% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 0.9% | 1.9% | ||
| Q3 25 | 0.9% | 1.5% | ||
| Q2 25 | 0.7% | 1.2% | ||
| Q1 25 | 0.6% | 4.7% | ||
| Q4 24 | 0.8% | 2.5% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.8% | 1.7% | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 2.92× | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
